WEKO3
アイテム
{"_buckets": {"deposit": "1f5fda9c-610e-4482-9181-0553f04382cf"}, "_deposit": {"created_by": 2, "id": "4326", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "4326"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00004326", "sets": ["11"]}, "author_link": ["17304", "17306", "17308", "17303", "17307", "17305", "17302"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2015-05", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "2", "bibliographicPageEnd": "200", "bibliographicPageStart": "195", "bibliographicVolumeNumber": "6", "bibliographic_titles": [{"bibliographic_title": "Clinical and Experimental Neuroimmunology"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Objectives Calcineurin inhibitors (CNI) are approved for the treatment of myasthenia gravis (MG) in Japan. However, the extent to which CNI have been effective remains unclear. Here we report data regarding CNI use and outcomes of MG. Methods We evaluated 640 consecutive MG patients by a multicenter survey. Patients not receiving any immune treatment were excluded, and cross-sectional and retrospective data of 515 patients receiving immune treatment with (n = 312) or without (n = 203) CNI were analyzed. Results Compared with patients treated without CNI, those treated with CNI had a higher frequency of MG Foundation of America Class III-V and higher severity disease at the worst clinical condition, and also had current higher severity, worse quality of life and higher daily doses of prednisolone, despite taking equivalent prednisolone dosages during the course of treatment. Achieving a treatment target was less frequent in the group treated with CNI. Onset age was not different between the two groups. Duration before CNI use after starting corticosteroids was 4.4 ± 6.3 years. Among those treated with CNI, late-onset MG patients achieved a more favorable current condition than did those with early-onset and thymoma-associated MG, whereas there was no such difference without CNI treatment. Conclusions CNI were given to severely ill MG patients with no attempt to select those more likely to respond, and failed to exert a strong impact on MG therapy. CNI should be given aggressively to patients with factors known to enhance susceptibility to these drugs, such as higher age at onset and early-stage disease.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Clinical and Experimental Neuroimmunology, 6(2), pp.195-200; 2015", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "日本神経免疫学会"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1111/cen3.12188", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "c 2015 Japanese Society for Neuroimmunology"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "17591961", "subitem_source_identifier_type": "ISSN"}]}, "item_2_text_62": {"attribute_name": "出版者別言語", "attribute_value_mlt": [{"subitem_text_value": "Japanese Society for Neuroimmunology"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Utsugisawa, Kimiaki"}], "nameIdentifiers": [{"nameIdentifier": "17302", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nagane, Yuriko"}], "nameIdentifiers": [{"nameIdentifier": "17303", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Imai, Tomihiro"}], "nameIdentifiers": [{"nameIdentifier": "17304", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Motomura, Masakatsu"}], "nameIdentifiers": [{"nameIdentifier": "17305", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Masuda, Masayuki"}], "nameIdentifiers": [{"nameIdentifier": "17306", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Konno, Shingo"}], "nameIdentifiers": [{"nameIdentifier": "17307", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Suzuki, Shigeaki"}], "nameIdentifiers": [{"nameIdentifier": "17308", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-21"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "CEN6_195.pdf", "filesize": [{"value": "74.6 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 74600.0, "url": {"label": "CEN6_195.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/4326/files/CEN6_195.pdf"}, "version_id": "005eab10-2c71-4363-99a3-12e221ad9565"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "calcineurin inhibitors", "subitem_subject_scheme": "Other"}, {"subitem_subject": "cyclosporine", "subitem_subject_scheme": "Other"}, {"subitem_subject": "myasthenia", "subitem_subject_scheme": "Other"}, {"subitem_subject": "quality of life", "subitem_subject_scheme": "Other"}, {"subitem_subject": "tacrolimus", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Treatment of myasthenia gravis patients with calcineurin inhibitors in Japan: A retrospective analysis of outcomes", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Treatment of myasthenia gravis patients with calcineurin inhibitors in Japan: A retrospective analysis of outcomes"}]}, "item_type_id": "2", "owner": "2", "path": ["11"], "permalink_uri": "http://hdl.handle.net/10069/35451", "pubdate": {"attribute_name": "公開日", "attribute_value": "2015-06-05"}, "publish_date": "2015-06-05", "publish_status": "0", "recid": "4326", "relation": {}, "relation_version_is_last": true, "title": ["Treatment of myasthenia gravis patients with calcineurin inhibitors in Japan: A retrospective analysis of outcomes"], "weko_shared_id": -1}
Treatment of myasthenia gravis patients with calcineurin inhibitors in Japan: A retrospective analysis of outcomes
http://hdl.handle.net/10069/35451
http://hdl.handle.net/10069/35451aa36824d-aa08-4c0c-93c2-71148a7a88c4
名前 / ファイル | ライセンス | アクション |
---|---|---|
CEN6_195.pdf (74.6 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2015-06-05 | |||||
タイトル | ||||||
タイトル | Treatment of myasthenia gravis patients with calcineurin inhibitors in Japan: A retrospective analysis of outcomes | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | calcineurin inhibitors | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | cyclosporine | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | myasthenia | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | quality of life | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | tacrolimus | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Utsugisawa, Kimiaki
× Utsugisawa, Kimiaki× Nagane, Yuriko× Imai, Tomihiro× Motomura, Masakatsu× Masuda, Masayuki× Konno, Shingo× Suzuki, Shigeaki |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Objectives Calcineurin inhibitors (CNI) are approved for the treatment of myasthenia gravis (MG) in Japan. However, the extent to which CNI have been effective remains unclear. Here we report data regarding CNI use and outcomes of MG. Methods We evaluated 640 consecutive MG patients by a multicenter survey. Patients not receiving any immune treatment were excluded, and cross-sectional and retrospective data of 515 patients receiving immune treatment with (n = 312) or without (n = 203) CNI were analyzed. Results Compared with patients treated without CNI, those treated with CNI had a higher frequency of MG Foundation of America Class III-V and higher severity disease at the worst clinical condition, and also had current higher severity, worse quality of life and higher daily doses of prednisolone, despite taking equivalent prednisolone dosages during the course of treatment. Achieving a treatment target was less frequent in the group treated with CNI. Onset age was not different between the two groups. Duration before CNI use after starting corticosteroids was 4.4 ± 6.3 years. Among those treated with CNI, late-onset MG patients achieved a more favorable current condition than did those with early-onset and thymoma-associated MG, whereas there was no such difference without CNI treatment. Conclusions CNI were given to severely ill MG patients with no attempt to select those more likely to respond, and failed to exert a strong impact on MG therapy. CNI should be given aggressively to patients with factors known to enhance susceptibility to these drugs, such as higher age at onset and early-stage disease. | |||||
書誌情報 |
Clinical and Experimental Neuroimmunology 巻 6, 号 2, p. 195-200, 発行日 2015-05 |
|||||
出版者 | ||||||
出版者 | 日本神経免疫学会 | |||||
出版者別言語 | ||||||
Japanese Society for Neuroimmunology | ||||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 17591961 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1111/cen3.12188 | |||||
権利 | ||||||
権利情報 | c 2015 Japanese Society for Neuroimmunology | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Clinical and Experimental Neuroimmunology, 6(2), pp.195-200; 2015 |